COMMENTARY

• GE Makers to Make Difficult Decision on Actos Generics due to Combination Patent
  June 6, 2011

• Effects of Changes to Accelerate Approval to Be Seen from November
  May 30, 2011

• Japan's Most Admired Pharma Companies in 2010
  April 4, 2011

• Will New Disclosure GL Promote Industry-Academia Alliances?
  March 28, 2011

• Use of Generics by Welfare Recipients
  March 7, 2011

• Wholesalers' Profits Drop Sharply Putting Premium for New Drug Development in Peril
  February 21, 2011

• Safety Measures Based on Common Medical Knowledge Questioned by Court: Iressa Affair
  February 21, 2011

• Recent Topics in Promising Anticancer Therapeutics
  January 17, 2011

• Development Race for Oral Anticoagulants Entering Final Stretch
  October 11, 2010

• How to Eliminate Concerns about Safety of Liovel
  October 4, 2010

• Will It Be Possible to Eliminate Unnecessary Equivalence Studies for Generics?
  September 20, 2010

• Big Pharma Losing Flagships within a Few Years and Shifting Paradigm
  September 13, 2010

• Prior Assessment System Is One Step Forward to Quicker NDA Review
  August 2, 2010

• Industry Needs to Form Consensus on Premium with Med. Institutions
  July 26, 2010

• Japan Should Promote Personalized Cancer Treatment
  July 26, 2010

• METI Reports on “Patent Box”Taxation System in Its Vision 2010
  July 5, 2010

• How Will Generics-Only Companies Will Compete with Major New Entrants?
  June 28, 2010

• Mr Hasegawa Calls For Cooperation with Asian Countries
  June 21, 2010

• PMDA Consultation for Clinical Drug Development in Japan
  April 26, 2010

• Taiyo Needs to Restart from Scratch
  April 19, 2010

ページ